Keywords: recombinant, calcitonin, osteoporosis, unigene, presented, results, its

Recombinant Calcitonin In Osteoporosis

Article | 08 July 1996

Print This

- Unigene has presented results of its latest Phase I clinical trial that demonstrates the efficacy at low doses of Fortical ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in